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BACKGROUND: QT interval, measured through a standard ECG, captures 
the time it takes for the cardiac ventricles to depolarize and repolarize. 
JT interval is the component of the QT interval that reflects ventricular 
repolarization alone. Prolonged QT interval has been linked to higher risk 
of sudden cardiac arrest.
METHODS AND RESULTS: We performed an ExomeChip-wide analysis 
for both QT and JT intervals, including 209 449 variants, both common 
and rare, in 17 341 genes from the Illumina Infinium HumanExome 
BeadChip. We identified 10 loci that modulate QT and JT interval 
duration that have not been previously reported in the literature using 
single-variant statistical models in a meta-analysis of 95 626 individuals 
from 23 cohorts (comprised 83 884 European ancestry individuals, 
9610 blacks, 1382 Hispanics, and 750 Asians). This brings the total 
number of ventricular repolarization associated loci to 45. In addition, 
our approach of using coding variants has highlighted the role of 17 
specific genes for involvement in ventricular repolarization, 7 of which 
are in novel loci.
CONCLUSIONS: Our analyses show a role for myocyte internal structure 
and interconnections in modulating QT interval duration, adding to 
previous known roles of potassium, sodium, and calcium ion regulation, 
as well as autonomic control. We anticipate that these discoveries will 
open new paths to the goal of making novel remedies for the prevention 
of lethal ventricular arrhythmias and sudden cardiac arrest.
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Prolonged QT interval has been associated with in-creased risk of sudden cardiac arrest (SCA), a ma-jor cause of mortality, with between 180 000 and 
450 000 cases of SCA in the United States of America 
annually.1 Because the vast majority of SCA occurs in 
the absence of clinical features that would bring a vic-
tim to medical attention,2 identifying additional risk fac-
tors and dissecting the pathogenesis of disease are of 
high importance.
Heritability estimates of QT interval are between 
30% and 40%, indicating that genetic variants play a 
large role in modulating QT interval in the general pop-
ulation.3 Mendelian syndromes of QT interval (long- 
and short-QT syndrome), which lead to increased risk 
of cardiac arrhythmias and SCA, occur in ≈1 in 2000 
individuals and are caused by variants in ion chan-
nels or their interacting proteins.4 Previous candidate 
gene and genome-wide association studies (GWAS), 
largely screening common noncoding variants, have 
identified 35 loci containing variants that modestly 
influence QT interval, the largest of these studies, the 
QT Interval International GWAS Consortium (QT-IGC),5 
included a discovery population of 76 061 European 
ancestry individuals.
In this study, we conduct ExomeChip-wide analyses 
in population-based samples to interrogate the role of a 
largely unstudied class of variation on ventricular repo-
larization in the population—coding single nucleotide 
variants (SNVs). These variants fill in the gap between 
the extremely rare large-effect coding variants that 
result in the Mendelian long- and short-QT syndromes 
and the common small-effect largely noncoding varia-
tion identified through GWAS. The focus on exons and 
coding variants has an added benefit of directly impli-
cating genes. By contrast, noncoding variation typically 
implicates a region of the genome, often containing 
multiple genes, and therefore requiring extensive func-
tional experiments to implicate a specific gene. Further-
more, in this study, we examine both QT and JT interval 
to more comprehensively examine ventricular repolar-
ization. We have previously observed that variation in 
specific loci can influence ventricular depolarization and 
repolarization in a concordant fashion.5,6
We performed a meta-analysis of 23 cohorts includ-
ing 95 626 multiethnic individuals comprised 83 884 
European ancestry individuals, 9610 blacks, 1382 His-
panics, and 750 Asian individuals (Table I in the in the 
Data Supplement). Each individual was genotyped for 
191 740 coding SNVs in 17 341 genes using the Illu-
mina Infinium HumanExome BeadChip (ExomeChip), 
along with 17 709 noncoding SNVs of known impor-
tance from previous GWAS and variants tiling across 
the genome. These variants were chosen by evaluat-
ing ≈12 000 exome sequences for coding variants that 
appeared in at least 3 individuals.
METHODS
The data, analytic methods, and study materials will be made 
available to other researchers for purposes of reproducing 
the results, subject to Data Use/Sharing Agreements adopted 
by individual participating cohorts. GWAS summary results 
will be available through the CHARGE Consortium Summary 
Results webpage available at dbGaP (phs000930).
This study was approved by local institutional review 
boards, and all participating subjects gave informed consent 
(detailed ethics statements in the Data Supplement).
SNV Association Tests and Meta-Analysis
Detailed methods are provided in the Data Supplement. 
Briefly, all cohorts excluded individuals with QRS intervals 
≥120 ms, heart rate <40 beats per minute or >120 beats per 
Clinical Perspective
Prolonged QT interval has been associated with 
increased risk of sudden cardiac arrest, a major 
cause of mortality, with between 180 000 and 
450  000 cases of sudden cardiac arrest in the 
United States of America annually. Because the 
vast majority of sudden cardiac arrest occurs in 
the absence of clinical features that would bring 
a victim to medical attention, identifying addi-
tional risk factors and dissecting the pathogen-
esis of disease are of high importance. In this 
study, we conduct ExomeChip-wide analyses in 
95 626 population-based multiethnic individu-
als to interrogate the role of a largely unstudied 
class of variation on ventricular repolarization in 
the population—coding single nucleotide vari-
ants. These variants fill in the gap between the 
extremely rare large-effect coding variants that 
result in the Mendelian long- and short-QT syn-
dromes and the common small-effect largely 
noncoding variation identified through genome-
wide association studies. The focus on exons and 
coding variants has an added benefit of directly 
implicating genes. Our approach of focusing on 
coding variants and both QT and JT intervals 
measures has identified 10 novel loci associated 
with ventricular repolarization and has implicated 
17 specific genes, 7 of which are in novel loci. 
Our analyses show a role for myocyte internal 
structure and interconnections in modulating QT 
interval duration, adding to previous known roles 
of potassium, sodium, and calcium ion regula-
tion, as well as autonomic control. We anticipate 
that these discoveries will open new paths to the 
goal of making novel remedies for the prevention 
of lethal ventricular arrhythmias and sudden car-
diac arrest.
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minute , left or right bundle branch block, atrial fibrillation on 
baseline ECG, Wolff–Parkinson–White syndrome, pacemaker, 
use of class I or class III blocking medication, or pregnant. 
Clinical characteristics summary statistics for each cohort are 
provided in Table I in the Data Supplement.
SNV effect size estimates are calculated via standard 
inverse variance–weighted meta-analysis of results provided 
by each cohort from a linear association model with QT/JT 
as the dependent variable, including covariates age, sex, RR 
interval (inverse heart rate), height, body mass index, and 
cohort-specific adjustments (principal components, clinic, 
family structure). Significance is similarly calculated by inverse 
variance–weighted meta-analysis; however, instead of raw 
QT/JT as the dependent variable in the linear regression, an 
inverse rank normal transformation is performed (details in 
the Data Supplement). These 2 models are used in tandem 
to avoid P value inflation from the analysis of the rare vari-
ants on the ExomeChip while maintaining the easy interpreta-
tion of effect sizes in milliseconds. The main analysis included 
all ethnic groups meta-analyzed together. SNVs with minor 
allele count <10 were excluded from the meta-analysis. SNVs 
were considered statistically significant if they exceeded the 
Bonferroni correction threshold of P<2×10−7.
Use of Functional Variants to Implicate 
Individual Genes Using Genome-Wide 
Significance
Genome-wide significance (GwiS) uses a greedy forward 
selection algorithm to identify independent genetic effects 
within a given gene/locus.7 A locus was defined by the SNV 
with the most significant association±1 megabase. GWiS was 
run on European-only summary statistics from 22 cohorts (QT, 
n=83 884; JT, n=80 330), with linkage disequilibrium (LD) esti-
mated from the merged ExomeChip and HapMap-imputed 
Atherosclerosis Risk in Communities (ARIC) European ancestry 
data set (n=9537; Data Supplement). An attempt to replace 
GWiS identified noncoding variants with equivalent coding 
variants (r2>0.8) did not yield any substitutions.
RESULTS
QT Interval ExomeChip Analysis 
Identifies 6 Novel Loci
Meta-analysis identified SNVs in 25 loci associated with 
QT interval at ExomeChip-wide significance (P<2×10−7; 
Figure I in the Data Supplement). Of these, 19 loci 
were previously associated with QT interval, and 6 loci 
were novel (Table 1). At 4 of these novel loci (PM20D1, 
SLC4A3, CASR, and NRAP), the top hit is a nonsynony-
mous variant. For the 2 novel loci where the index SNV 
is a noncoding variant, no genes in these loci harbored 
coding SNVs associated with QT interval. Analyses 
stratified by ethnicity found similar effect sizes between 
European ancestry individuals and blacks and same 
general direction of effects in the much smaller Hispan-
ics (n=1382) and Chinese (n=750) cohorts (Table II and 
Figure II in the Data Supplement).
Nineteen of the 25 loci associated with QT interval 
at ExomeChip-wide significance in our study had been 
associated with QT interval in prior European ancestry 
GWAS studies (Table 2, *P value). Table 2 detail the 35 
known QT loci identified from prior GWAS of Europe-
an ancestry individuals. Of the 14 previously identified 
loci for which the most significant SNV in our current 
study is a coding variant (Table 2, A), 3 loci reached 
ExomeChip-wide significance in our study (*P value). 
Of the 21 previously identified loci for which the most 
significant SNV in our study is a noncoding variant 
not in LD (r2>0.8) with a nearby coding variant, 16 
loci exceeded the significance threshold in our study 
(Table  2, B, *P value). For 5 of these 16 loci where 
the top signal was a noncoding SNV, they nonetheless 
harbored coding variants in ≥1 nearby genes that also 
reached ExomeChip-wide significance (Table II in the 
Data Supplement).
Table 1. Six Novel Loci Associated With QT Interval
Nearby 
Gene SNV Chr
Coded/ 
Noncoded  
Allele CAF
Effect in ms 
(SE) P Value Function
Gene(s) With 
Independent 
Coding 
Variation
DEPICT 
Implicated 
Gene(s) eQTL
PM20D1
rs1361754 1 G/A 0.511 0.47 (0.08) 1E-09 Nonsynonymous PM20D1
 PM20D1,*  
NUCKS1, RAB7L1,* 
SLC41A1
SLC4A3 rs55910611 2 A/G 0.006 −3.06 (0.61) 2E-07 Nonsynonymous SLC4A3   
CASR rs1801725 3 T/G 0.126 −0.58 (0.12) 4E-08 Nonsynonymous CASR  CSTA
ZNF37A rs4934956 10 T/C 0.497 0.58 (0.10) 2E-10 Intergenic    
NRAP rs3189030 10 A/G 0.299 −0.48 (0.09) 4E-08 Nonsynonymous NRAP NRAP CASP7*
GOSR2 rs17608766 17 C/T 0.123 0.72 (0.12) 3E-09 UTR3   RPRML
Significance was determined from analysis of inverse rank normal transformed residuals to avoid P value inflation from the analysis of rare variants. Effect 
size estimates in milliseconds (ms) are reported from untransformed analyses. n=95 626 number of samples. DEPICT9 genes pass FDR <5% cutoff. Expression 
quantitative trait loci (eQTL) genes are pulled from the Genotype-Tissue Expression portal10,11 using the representative SNV and GWiS independent SNVs. CAF 
indicates coded allele frequency; DEPICT, Data-driven Expression-Prioritized Integration for Complex Traits; FDR, false discovery rate; GwiS, genome-wide 
significance; SNV, single-nucleotide variants; and UTR3, three prime untranslated region.
*Gene if the eQTL is in the left ventricle.
D
ow
nloaded from
 http://ahajournals.org by on August 13, 2019
Bihlmeyer et al; ExomeChip Identifies 10 Novel QT Loci
Circ Genom Precis Med. 2018;11:e001758. DOI: 10.1161/CIRCGEN.117.001758 January 2018 4
Table 2. Thirty-Five Loci Previously Associated With QT Interval
Nearby Gene SNV Chr
Coded/ 
Noncoded 
Allele CAF
Effect in 
ms (SE) P Value Function
QT-IGC 
Implicated 
Gene(s)
Gene(s) 
With 
Independent 
Coding 
Variation
DEPICT 
Implicated 
Gene(s) eQTL
A, Known QT loci with coding variant as top SNV
  RNF207 rs709209 1 G/A 0.379 1.23 (0.09) 1E-48* Nonsynonymous RNF207(c) RNF207 RNF207 GPR153
  SP3 rs1047640 2 C/T 0.120 0.60 (0.12) 3E-06 Nonsynonymous  SP3   
  TTN-
CCDC141
rs72648998 2 T/C 0.054 1.00 (0.18) 3E-09*
Nonsynonymous CCDC141(i), 
TTN(i)
TTN
 FKBP7, 
PRKRA
  SPATS2L
rs192861441 2 A/G 0.004 −2.22 (0.67) 3E-04 Nonsynonymous
SPATS2L(t), 
SGOL2(p)
   
  C3ORF75
rs2276853 3 G/A 0.411 −0.36 (0.08) 2E-05 Nonsynonymous
KLHL18(t), 
PTPN23(t), 
SCAP(t), SETD2(t), 
MYL3(i)
 
NBEAL2
NBEAL2, 
PTPN23, 
SCAP
  SMARCAD1 rs7439869 4 T/C 0.378 0.41 (0.08) 8E-07 Nonsynonymous  SMARCAD1   
  GMPR
rs1042391 6 T/A 0.551 −0.42 (0.09) 3E-06
Nonsynonymous GMPR(c), 
ATXN1(tp)
GMPR  GMPR
  KCNH2 rs1805123 7 G/T 0.214 −1.47 (0.10) 7E-51* Nonsynonymous KCNH2(p) KCNH2†  KCNH2
  LAPTM4B rs17831160 8 A/G 0.030 −0.64 (0.24) 3E-03 Nonsynonymous     
  AZIN1 rs143025416 8 A/G 0.001 4.90 (1.55) 2E-03 Nonsynonymous     
  GBF1
rs143226354 10 T/C 8.89E-05 14.18 (4.66) 4E-03
Splicing/ 
nonsynonymous
ACTR1A(i)
   
  ATP2A2
rs11068997 12 A/G 0.040 −0.94 (0.21) 4E-07 Nonsynonymous
VPS29(t),  
GPN3(t), 
ARPC3(t), 
C12ORF24(t), 
ATP2A2(pi)
GIT2, TCTN1
ATP2A2, 
PPTC7
 
  USP50-
TRPM7 rs8042919 15 A/G 0.097 −0.57 (0.14) 4E-05 Nonsynonymous
   SPPL2A, 
AP4E1, 
USP50
  CREBBP rs143903106 16 T/G 0.001 4.10 (1.46) 5E-03 Nonsynonymous TRAP1(i)    
B, Known QT loci with noncoding variant as top SNV
  TCEA3
rs1077514 1 G/A 0.179 −0.58 (0.11) 4E-08* Intronic
TCEA3(t)   TCEA3,‡ 
ASAP3
  NOS1AP rs12143842 1 T/C 0.240 3.18 (0.10) 3E-255* Intergenic     
  ATP1B1
rs10919071 1 G/A 0.115 −1.37 (0.13) 3E-30* Intronic
ATP1B1(ti), 
NME7(t)
  NME7
  SLC8A1 rs2540226 2 T/G 0.482 0.24 (0.08) 2E-03 Intergenic SLC8A1(p)   THUMPD2
  SCN5A-
SCN10A
rs12053903 3 C/T 0.379 −0.88 (0.09) 1E-26* Intronic SCN5A(p) SCN10A SCN5A
SNORA6, 
SCN5A§
  SLC4A4 rs7689609 4 C/T 0.212 0.64 (0.12) 4E-08* Intronic     
  GFRA3
rs4835768 5 G/A 0.485 0.34 (0.08) 7E-05 Intergenic
FAM13B(t), 
ETF1(p)
 MYOT, 
FAM13B
 
  SLC35F1-PLN rs11153730 6 C/T 0.467 1.41 (0.08) 5E-74* Intergenic PLN(i)  PLN SSXP10
  CAV1
rs3807989 7 A/G 0.429 0.54 (0.08) 4E-12* Intronic
CAV1(pi), 
CAV2(pi)
  AC002066.1
  NCOA2 rs2926707 8 G/T 0.348 0.31 (0.09) 3E-04 Intronic     
  KCNQ1
rs2074238 11 T/C 0.074 −3.58 (0.16) 8E-130* Intronic
C11ORF21(t), 
PHEMX(t), 
TSPAN32(t), 
KCNQ1(p)
KCNQ1 KCNQ1
 
  FEN1-FADS2
rs1535 11 G/A 0.325 −0.48 (0.09) 8E-10* Intronic
FADS1(t), 
FADS2(t), 
FADS3(t)
  FAD2,‡ 
FADS1, 
TMEM258
  KLF12 rs1886512 13 A/T 0.381 0.57 (0.09) 2E-10* Intronic KLF12(t)   KLF12‡
  ANKRD9 rs11704 14 C/G 0.291 0.35 (0.09) 7E-05 UTR3 ANKRD9(t)  ANKRD9 ZNF839
(Continued )
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JT Interval Association Identifies  
4 Novel Loci
Although ventricular depolarization and repolarization 
are often coregulated, this is not universally true. There-
fore, to more specifically examine ventricular repolariza-
tion, we also investigated genetic associations with JT 
interval, defined mathematically by subtracting the QRS 
interval (ventricular depolarization and conduction) 
from the QT interval, which primarily reflects ventricular 
repolarization.8 Among the 15 590 ARIC participants, 
the correlations (r2) among the intervals were 0.84 for 
QT and JT; 0.02 for QRS and JT; and 0.08 for QT and 
QRS. We analyzed JT interval as described above for 
QT interval while adding QRS interval as an additional 
covariate to further remove the effect of ventricular 
depolarization on the analysis. Thirty coding variants in 
14 loci were associated with JT interval (Table III and 
Figure III in the Data Supplement). Four of these 14 loci 
were not identified as QT interval loci (Table 3). Three 
of these 4 novel repolarization loci had index SNVs that 
were coding variants: SENP2, SLC12A7, and NACA. The 
SNV rs9470361 (near CDKN1A) has previously been 
associated with QRS interval with an effect size esti-
mate in the opposite direction (Table 3). Indeed, for 3 
of these loci (SENP2, CDKN1A, and NACA), where an 
association was found with JT but not with QT interval, 
the index SNVs were significantly associated with QRS 
duration but with effect estimates in the opposite direc-
tion (Table 3). Hence, at these loci, variants that prolong 
the QRS interval (depolarization) shorten the JT inter-
val (repolarization). Analyses run stratified by ethnicity 
found similar effect sizes between European ancestry 
individuals and blacks (Table III in the Data Supplement).
Use of Coding Variants to Implicate 
Specific Genes
Leveraging information from nominally significant cod-
ing SNVs, we sought to implicate causative genes in 
each locus by demonstrating that putatively functional 
coding variants are associated with ventricular repo-
larization independently of noncoding SNVs. We have 
previously5 shown that several QT loci contain multiple 
independent genetic effects, including some loci har-
boring multiple significant coding variants (Tables II and 
III in the Data Supplement). Thus, even if not the top hit 
at a locus, putative functional SNVs can still implicate a 
specific gene at a locus. We used the GWiS7 algorithm to 
determine the number of independent effects in all 45 
ventricular repolarization associated loci from Tables 1 
through 3 and to identify the SNV that best represents 
each independent effect in European ancestry indi-
viduals (n=83 884; Table IV in the Data Supplement). 
The SCN5A-SCN10A locus is a particularly illustrative 
example of the use of this approach. Although cod-
ing variants in DLEC1, SCN5A, and SCN10A are each 
ExomeChip-wide significant, after using GWiS, the 
  LITAF rs8049607 16 T/C 0.503 1.05 (0.08) 8E-44* Intergenic LITAF(t)   LITAF‡
 MKL2 rs30208 16 T/C 0.501 0.45 (0.08) 2E-09* Intergenic     
  CNOT1
rs7188697 16 G/A 0.247 −1.57 (0.10) 4E-63* Intronic
NDRG4(t), 
CNOT1(t), GOT2(i)
  SETD6, 
NDRG4
  LIG3
rs2074518 17 A/G 0.428 −0.79 (0.08) 2E-21* Intronic
LIG3(t), CCT6B(t), 
UNC45B(i)
  LIG3,‡ 
CCT6B, 
RFFL,‡ RP5-
837J1.2
  PRKCA rs9912468 17 G/C 0.417 −0.68 (0.08) 2E-15* Intronic PRKCA(t)   PRKCA‡
  KCNJ2 rs17779747 17 T/G 0.304 −1.08 (0.09) 3E-37* Intergenic     
  KCNE1 rs727957 21 T/G 0.168 0.48 (0.11) 3E-05 Intronic KCNE1(cp)    
A section lists the 14 (of 35) previously identified loci (QT-IGC study of European ancestry individuals5) for which the most significant SNV in our current study is a coding 
variant. Because of the design of the Exome Chip with a focus on coding variants, only select intronic or intergenic SNVs were interrogated, and therefore not all QT-IGC 
SNVs were examined. B section lists the 21 previously identified loci for which the most significant SNV in our study is a noncoding variant not in LD (r2>0.8) with a nearby 
coding variant. Significance was determined from analysis of inverse rank normal transformed residuals to avoid P value inflation from the analysis of rare variants. Effect size 
estimates in milliseconds (ms) are reported from untransformed analyses. n=95 626 number of samples. Within the QT-IGC Implicated Gene(s) column, evidence for the gene 
is c, coding variant; t, eQTL transcript; p, in silico protein-protein interactor; i, immunoprecipitation interactor. DEPICT9 genes pass FDR<5% cutoff. Expression quantitative trait 
loci (eQTL) genes are pulled from the Genotype-Tissue Expression portal10,11 using the representative SNV and GWiS independent SNVs. CAF indicates coded allele frequency; 
DEPICT, Data-driven Expression-Prioritized Integration for Complex Traits; FDR, false discovery rate; GwiS, genome-wide significance; QT-IGC, QT Interval International GWAS 
Consortium, and SNV, single nucleotide variants.
*P value if significantly associated after Bonferroni correction, P<2×10−7.
‡Gene if the eQTL is in the left ventricle.
§GWiS independent SNV rs9851724 used to identify eQTL.
†Conditional analyses in ARIC contradict this result, see text for details.
Table 2. Continued
Nearby Gene SNV Chr
Coded/ 
Noncoded 
Allele CAF
Effect in 
ms (SE) P Value Function
QT-IGC 
Implicated 
Gene(s)
Gene(s) 
With 
Independent 
Coding 
Variation
DEPICT 
Implicated 
Gene(s) eQTL
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signal coming from the coding variants in DLEC1 and 
SCN5A is explained by noncoding variants, and only 
the SCN10A coding variant signal remains (Table V in 
the Data Supplement). In the Gene(s) with independent 
coding variation column in Tables 1 through 3, we list 
the 17 genes in 16 loci that have an independent effect 
represented by a coding variant.
For the loci listed in Table 2 B, such as the SCN5A-
SCN10A locus, where intronic and intergenic variants 
were included in the analyses, the independent associa-
tions in coding SNVs identified by GWiS are independent 
of the noncoding variants in the region. This analysis 
implicates 2 genes for involvement in cardiac repolariza-
tion among those of European descent: SCN10A and 
KCNQ1. For the novel loci in Table  1 where a coding 
SNV is the most significant association in our study, it is 
unlikely that noncoding variants of importance are pres-
ent in those loci because the loci were not found during 
the QT-IGC efforts, a study of similar sample size.
In contrast, for the 14 previously identified QT loci 
where the top SNV in our study was a coding variant 
(Table 2, A), the GWiS findings are less conclusive because 
intronic and intergenic SNVs were largely not examined 
in these regions. Therefore, to determine whether the 
associated coding variants are independently associated 
with QT interval and hence implicate a causal gene, or 
alternatively, are associated simply because of LD with a 
more strongly associated noncoding variant not geno-
typed with the ExomeChip, we performed additional 
analyses in a subset of the data set, ARIC, that includes 
both the QT-IGC top SNV, as well as the top SNV, from 
the current study. We performed conditional analyses at 
the 7 loci in Table 2, A where significant associations were 
identified by GWiS (the remaining 7 loci did not have any 
SNVs identified as significant by GWiS after accounting 
for multiple testing), by including both the QT-IGC and 
ExomeChip variants in the same regression model in the 
ARIC Europeans data set (n=9537; Table VI in the Data 
Supplement). Conditional analyses demonstrate that the 
coding variant in SP3 is independent of the top noncod-
ing SNV at this locus discovered from QT-IGC, implicat-
ing this gene in QT interval modulation. For GMPR, the 
coding variant is in almost perfect linkage disequilibrium 
with the noncoding QT-IGC variant (r2=0.99 in ARIC), 
suggesting that the coding variant may be the causal 
variant explaining the QT-IGC signal. For a third locus, 
RNF207, although conditional analysis suggested that 
the QT-IGC SNV accounts for the association at this locus, 
both the top QT-IGC SNV as well as the top SNV from 
this study are coding variants in high LD, thus implicat-
ing the RNF207 gene in myocardial repolarization. For the 
remaining 4 loci, 1 coding variant is associated because of 
the stronger noncoding QT-IGC signal (KCNH2); 2 were 
not properly tested because of no effect in ARIC of the 
ExomeChip variant (ATP2A2) or the QT-IGC variant (TTN), 
although there was low LD (r2<0.04) between the coding 
and noncoding variants, suggesting independence; and 
1 was unclear (SMARCAD1), as putting both SNVs in the 
model significantly altered the β estimates for both SNVs.
In Silico Analyses to Implicate Causal Genes
To further decode the role these loci might play in regu-
lating ventricular repolarization, Data-driven Expression-
Prioritized Integration for Complex Traits9 was used to 
investigate whether identified loci contain genes from 
functional annotated gene sets/pathways. Included in 
Tables  1 through 3 in the DEPICT Implicated Gene(s) 
column is a list of genes with a false discovery rate 
<5%. Furthermore, we looked up each of the Tables 1 
through 3 SNVs in the Genotype-Tissue Expression Por-
tal to identify single-tissue expression quantitative trait 
loci10,11 (left ventricle expression quantitative trait loci, 
represented by footnote symbols in tables). Findings for 
Table 3. Four Novel Loci Associated With JT Interval
Nearby 
Gene SNV Chr
Coded/ 
Noncoded 
Allele CAF
JT Effect  
in ms (SE)
JT P 
Value
QRS Effect  
in ms (SE)
QRS P 
Value Function
Gene(s) With 
Independent 
Coding 
Variation
DEPICT 
Implicated 
Gene(s) eQTL
SENP2 rs6762208 3 A/C 0.358 0.44 (0.08) 2E-07* −0.31 (0.05) 3.45E-12* Nonsynonymous SENP2   
SLC12A7
rs737154 5 C/T 0.500 −0.40 (0.08) 2E-07* 0.07 (0.04) 8.84E-02
Splicing/ 
synonymous
SLC12A7  NKD2
CDKN1A rs9470361 6 A/G 0.249 −0.76 (0.09) 2E-15* 0.84 (0.05) 1.21E-63* Intergenic    
NACA rs2926743 12 A/G 0.252 0.53 (0.09) 6E-08* −0.32 (0.05) 9.40E-11* Nonsynonymous NACA RBMS2  
Significance was determined from analysis of inverse rank normal transformed residuals to avoid P value inflation from the analysis of rare variants. Effect 
size estimates in milliseconds (ms) are reported from untransformed analyses. QRS interval association summary data for these 4 variants were contributed by 
our coauthors Drs Prins, Jamshidi, and Arking from ExomeChip analyses they are running as a part of the Cohorts for Heart and Aging Research in Genomic 
Epidemiology (CHARGE) Consortium Electrocardiogram (EKG) working group. n=95 626 samples for JT interval association and n=85 593 samples for QRS interval 
association. DEPICT9 genes pass FDR<5% cutoff. Expression quantitative trait loci (eQTL) genes are pulled from the Genotype-Tissue Expression portal10,11 using the 
representative SNV and GWiS independent SNVs. CAF indicates coded allele frequency; DEPICT, Data-driven Expression-Prioritized Integration for Complex Traits; 
FDR, false discovery rate; GwiS, genome-wide significance; and SNV, single nucleotide variants.
*P value if significantly associated after Bonferroni correction, P<2×10−7.
†Gene if the eQTL is in the left ventricle.
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Data-driven Expression-Prioritized Integration for Com-
plex Traits and expression quantitative trait loci analy-
ses are largely consistent with those genes identified 
because of harboring significant coding variants and 
help clarify the causative gene.
DISCUSSION
Our approach of focusing on coding variants and both 
QT and JT intervals has identified 10 novel loci associ-
ated with ventricular repolarization and has implicated 
17 specific genes, 7 of which are in novel loci. Previous 
studies have implicated roles for potassium ion regu-
lation, sodium ion regulation, calcium ion regulation, 
and autonomic control of QT interval,12 and our results 
provide support for each of these pathways. SLC12A7 
(KCC4), which is highly expressed in the left ventri-
cle,10,11 is a potassium chloride cotransporter involved in 
potassium efflux.13 CASR is a G protein–coupled recep-
tor that maintains circulating calcium ion homeostasis 
via parathyroid hormone secretion in the parathyroid 
and kidney tubule ion handling.14
In addition to previously implicated pathways, our 
analyses highlight a role for genes involved in generating 
the physical force of contraction inside of cardiomyocytes 
and for conducting electric signal between cardiomyo-
cytes across the heart. Pathway enrichment analyses 
using Data-driven Expression-Prioritized Integration for 
Complex Traits (detailed methods in the Data Supple-
ment) identified the GO category GO:0005916, which 
comprised the genes that code for fascia adherens, the 
structure that links myofibrils between cardiomyocytes, 
and contains N-cadherin. NRAP, found to have a signifi-
cant independent coding variant, likely anchors terminal 
actin filaments of myofibrils to other protein complexes 
beneath the sarcolemma15,16 and is expressed exclusively 
in skeletal muscle and heart.10,11 skNAC (skeletal NACA) 
knockout mice, a muscle-specific isoform of NACA, 
which was found to have a significant independent cod-
ing variant, die between embryonic days 10.5 and 12.5 
because of cardiac defects, showing interventricular sep-
tal defects and a thin myocardial wall.17 With these 3 
points of evidence combined with the previously known 
locus and GWiS-implicated gene, TTN, a clear class of 
genes emerge that influence ventricular repolarization 
through their effect on myocyte structure.
It is important to note that the intercalated disc, 
which is the interface between cardiomyocytes, con-
tains fascia adherens, desmosomes, and gap junctions, 
the last of which is known to play a role in ion-medi-
ated relaying of action potentials between cardiomyo-
cytes and, in combination with the gene NOS1AP, has 
been implicated as regulating QT interval.18 In contrast, 
we implicate a nonion-dependent structural/mechani-
cal interconnect between cardiomyocytes mediated by 
the fascia adherens.
By looking specifically at ventricular repolarization (JT 
interval) without the influence of depolarization (QRS 
interval), we detected additional loci related to ventric-
ular repolarization while teasing apart the differential 
regulation of the various phases of ventricular conduc-
tion. Our current results are consistent with our prior 
findings that variation in some loci influence ventricular 
depolarization and repolarization in a concordant fash-
ion, others influence depolarization and repolarization 
in a discordant fashion, and still other loci are associat-
ed with one phenotype and not the other.5,6 Although 
ventricular depolarization and repolarization are often 
coregulated, the difference in genetic effect indicates 
this is not universally true. Several limitations should be 
noted. First, we did not have an additional sample to 
perform replication studies although results were con-
sistent across the diverse cohorts included in our study 
(Figures IV–XIII in the Data Supplement). Second, cor-
relation of effect sizes was weak between the European 
ancestry and Hispanic and Asian populations, limiting 
extrapolation of findings to these populations.
In summary, we have identified 10 loci newly asso-
ciated with ventricular repolarization. This brings the 
total number of ventricular repolarization–associated 
loci to 45. In addition, we have directly implicated 17 
specific genes contained in these loci as likely affecting 
ventricular repolarization and outlined a class of genes 
that mechanically control QT interval. These new dis-
coveries will likely allow for the development of novel 
vectors for the prevention of lethal ventricular arrhyth-
mias and SCA.
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